Delaware
|
84-1475642
|
|
(State
or other jurisdiction of
|
|
(I.R.S.
Employer
|
Incorporation
or organization)
|
1180
Avenue of the Americas, 19th
Floor
New
York, New York 10036
Telephone
(212) 214-0700
|
Identification
No.)
|
Title
of
Securities
to be Registered
|
Proposed
Maximum Amount to be
Registered
|
Proposed
Maximum
Offering
Price
Per
Share (1)
|
Aggregate
Offering
Price (1)
|
Amount
of
Registration
Fee
|
Common
Stock, par value $.001 per share
|
1,252,435
|
$4.50
|
$5,635,958
|
$663.35
|
(1) |
Estimated
solely for the purpose of determining the registration fee pursuant
to
Rule 457(c) and (h) and based upon the average low and high sales
prices
of the Registrant’s Common Stock on November 16, 2005, as reported on the
OTC bulletin board.
|
(a)
|
Annual
Report on Form 10-KSB for the fiscal year ended December 31, 2004
filed on
March 31, 2005;
|
(b)
|
Prospectus
filed on November 18, 2005 pursuant to Rule 424(b) promulgated
under the
Securities Act of 1933, as amended, which prospectus contains the
Registrant’s audited financial
statements;
|
(c)
|
Quarterly
Report on Form 10-QSB for the quarter ended March 31, 2005 filed
on May
13, 2005;
|
(d)
|
Quarterly
Report on Form 10-QSB for the quarter ended June 30, 2005 filed
on August
12, 2005, and as amended on August 15, 2005;
|
(e)
|
Quarterly
Report on Form 10-QSB for the quarter ended September 30, 2005
filed on
November 10, 2005;
|
(f)
|
Current
Reports on Form 8-K filed on August 9, 2005, August 24, 2005 and
September
19, 2005; and
|
(g)
|
Registration
Statement on Form SB-2 filed November 14, 2005, containing the
description
of capital stock as set forth in the section entitled “Description of
Capital Stock”
|
Exhibit
|
Description
|
|
4.1
|
ZIOPHARM
Oncology, Inc. 2003 Stock Option Plan (incorporated by reference
to
Exhibit 10.1 to the Registrant’s Registration Statement on Form SB-2, SEC
File No. 333-129020, filed on October 14, 2005)
|
|
5.1
|
Opinion
of Maslon Edelman Borman & Brand, LLP as to the legality of the
securities being registered
|
|
23.1
|
Consent
of Independent Registered Public Accounting Firm - Vitale, Caturano
&
Company, Ltd.
|
|
23.2
|
Consent
of Independent Registered Public Accounting Firm - Cordovano and
Honeck,
LLP
|
|
23.3
|
Consent
of Maslon Edelman Borman & Brand, LLP (included in Exhibit
5.1)
|
|
24.1
|
Power
of Attorney (included on signature page
hereof)
|
(a)
|
The
undersigned registrant hereby
undertakes:
|
(1) |
To
file, during any period in which offers or sales are being made,
a
post-effective amendment to this registration
statement:
|
ZIOPHARM
Oncology, Inc.
|
||
|
|
|
By: | /s/ Jonathan Lewis | |
Jonathan Lewis |
||
Chief Executive Officer |
Name
|
Title
|
Date
|
||
/s/
Jonathan Lewis
|
Director
and Chief Executive Officer (Principal Executive Officer)
|
November
22, 2005
|
||
Jonathan
Lewis
|
||||
/s/
Richard Bagley
|
Director,
President, Treasurer and Chief Operating Officer (Principal Accounting
and
Financial Officer)
|
November
22, 2005
|
||
Richard
Bagley
|
||||
/s/
Murray Brennan
|
Director
|
November
22, 2005
|
||
Murray
Brennan
|
||||
|
Director
|
November
22, 2005
|
||
James
Cannon
|
||||
/s/
Timothy McInerney
|
Director
|
November
22, 2005
|
||
Timothy
McInerney
|
||||
/s/
Wyche Fowler, Jr.
|
Director
|
November
22, 2005
|
||
Wyche
Fowler, Jr.
|
||||
|
Director
|
November
22, 2005
|
||
Gary
S. Fragin
|
||||
/s/
Michael Weiser
|
Director
|
November
22, 2005
|
||
Michael
Weiser |
Exhibit
|
Description
|
|
5.1
|
Opinion
of Maslon Edelman Borman & Brand, LLP as to the legality of the
securities being registered
|
|
23.1
|
Consent
of Independent Registered Public Accounting Firm - Vitale, Caturano
&
Company, Ltd.
|
|
23.2
|
Consent
of Independent Registered Public Accounting Firm - Cordovano and
Honeck,
LLP
|
|
23.3
|
Consent
of Maslon Edelman Borman & Brand, LLP (included in Exhibit
5.1)
|
|
24.1
|
Power
of Attorney (included on signature page
hereof)
|